Atara Biotherapeutics Announces Primary Analysis Data From Phase 2 EMBOLD Clinical Trial Of ATA188 In Non-Active Progressive Multiple Sclerosis; Primary Endpoint Of Confirmed Disability Improvement At 12 Months Not Achieved
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics announced that its Phase 2 EMBOLD clinical trial of ATA188 for non-active progressive multiple sclerosis did not meet the primary endpoint of confirmed disability improvement at 12 months. The company plans to further analyze the data and evaluate strategic options for the ATA188 program. Despite the setback, Atara plans to focus resources on advancing its allogeneic CAR-T portfolio and expects to extend its cash runway beyond Q3 2025.
November 08, 2023 | 11:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Atara Biotherapeutics' Phase 2 trial of ATA188 did not meet its primary endpoint, which may negatively impact the company's stock in the short term. However, the company's focus on its CAR-T portfolio and expected cash runway extension could mitigate this impact.
The failure of a Phase 2 clinical trial is a significant setback for any biotech company, as it represents a substantial investment of time and resources. This could lead to a negative reaction from investors, driving the stock price down. However, Atara's focus on its CAR-T portfolio and its financial stability could help offset this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100